Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotech, medical technology, and health solutions companies. The firm focuses on companies with therapies, devices, diagnostics, and services that significantly improve the lives of patients and provide solid returns for investors.

David Hirsch

Marc Galletti

Patrick Enright

Longitude Capital

Visionary Ventures is a venture capital fund focused on investing in companies from series A to commercialization, aiming for investments that yield exceptional returns and address unmet or underserved markets. The company collaborates with Key Opinion Leaders and industry experts to inform their investment decisions.

Visionary Ventures

Longitude Capital specializes in making venture growth investments in biotechnology, medical technology and health solutions companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. Longitude Capital invests in both privately held and publicly traded life science companies through a variety of investment approaches. Media Contact:Maggie Jamisonmjamison@longitudecapital.com

Esperion

Jazz Pharmaceuticals

Collegium Pharmaceutical

RxSight

Kala Pharmaceuticals

Molecular Templates

Vaxcyte

Talaris Therapeutics

Tricida

Vera Therapeutics

Venus Concept

Inozyme

Poseida Therapeutics

Practice Fusion

Rapid Micro Biosystems

89bio

Aimmune Therapeutics

Amunix

Aptinyx

Eargo

Axonics Modulation Technologies

Metric
Company Name	Longitude Capital	Visionary Ventures
Symbol
MSH ID	COM:LONGITUDECAPITAL	COM:VISIONARYVC
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Financial Services & Finance
Industry	Healthcare	Venture Capital
Country	US	US
Stage
Employee Count	42
Website	longitudecapital.com	visionaryvc.com
LinkedIn	longitude-capital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:LONGITUDECAPITAL

Longitude Capital

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue